Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about EXELIXIS, INC.
01/19Exelixis Reports Trial Results For Cabozantinib in Combination With Immunotherapies to ..
MT
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
BU
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
CI
01/10EXELIXIS : Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Prov..
PU
01/10Exelixis Expects Net Product Revenue of $300 Million for Q4, $1.08 Billion for Full-Yea..
MT
01/09Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Pro..
BU
01/09Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter a..
CI
01/06Exelixis to Pay $55 Million to Amend Licensing Deal With Iconic Therapeutics, Gains Ful..
MT
01/06Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antib..
BU
01/05Exelixis, Roche Complete Enrollment in Phase 3 Trial of Kidney Cancer Combination Thera..
MT
01/05Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Developm..
AQ
01/05Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozan..
BU
01/05Exelixis, Inc. Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of C..
CI
01/04Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on Jan..
BU
01/04Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Developm..
BU
01/04Exelixis, Inc. Appoints Vicki L. Goodman as Executive Vice President, Product Developme..
CI
2021Adagene Will Receive $3 Million for Successful Nomination of SAFEbody Candidates in Col..
MT
2021Exelixis Elects Jacqueline Wright to Its Board of Directors
AQ
2021Exelixis Elects Jacqueline Wright to Its Board of Directors
BU
2021Exelixis, Inc. Appoints Jacqueline Wright to Its Board of Directors, as Member of the N..
CI
2021Exelixis Starts Trial of Advanced Cancers Treatment in Combination With Immuno-Oncology..
MT
2021Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Im..
BU
2021Exelixis, Inc. Announces Initiation of Phase 1B Trial Evaluating XL092 in Combination w..
CI
2021Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
AQ
2021Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
BU
2021Exelixis Announces Detailed Results from Phase 3 Cosmic-312 Pivotal Trial of Cabozantin..
CI
2021Exelixis Says Enrollment Complete For Phase 3 Trial For Cabozantinib in Combination Wit..
MT
2021Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
BU
2021Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
CI
2021Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November ..
BU
2021Jefferies Starts Exelixis' at Buy with $28 Price Target
MT
2021Fresh data highlights strength of US economy ahead of Fed meeting
2021HC Wainwright Adjusts Price Target on Exelixis to $52 From $65, Keeps Buy Rating
MT
2021Exelixis Posts Higher Q3 Results, Guides Full-Year Revenue Below Street Views; Shares S..
MT
2021EXELIXIS : Q3 Earnings Snapshot
AQ
2021Exelixis Q3 Earnings Slides With Appendix
PU
2021EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE -..
PU
2021Earnings Flash (EXEL) EXELIXIS Posts Q3 Revenue $328.4M, vs. Street Est of $355.1M
MT
2021Earnings Flash (EXEL) EXELIXIS Reports Q3 EPS $0.20, vs. Street Est of $0.26
MT
2021Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
BU
2021Exelixis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
2021Exelixis, Inc. Provides Earnings Guidance for the Full Year 2021
CI
2021EARNINGS REACTION HISTORY : Exelixis Inc, 30.0% Follow-Through Indicator, 4.4% Sensitive
MT
2021Oppenheimer Adjusts Exelixis' Price Target to $29 From $30, Maintains Outperform Rating
MT
2021EXELIXIS : to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
BU
2021INSIDER SELL : Exelixis
MT
2021EXELIXIS : In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance ..
AQ
2021EXELIXIS : Storm Therapeutics Sign Collaboration, License Deal to Discover Cancer Treatmen..
MT
2021EXELIXIS : In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance ..
BU
2021EXELIXIS : and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement..
BU
2021Exelixis, Inc. Exercises Exclusive Option Under the Companies’ July 2019 Agreement
CI
2021EXELIXIS : Jefferies Starts Exelixis at Buy with $28 Price Target
MT
2021EXELIXIS : Reports Final Results From Phase 3 Trial of Thyroid Cancer Treatment
MT
2021EXELIXIS : Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in ..
BU
2021Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in..
CI
2021EXELIXIS : Announces U.S. FDA Approval of CABOMETYX (cabozantinib) for Patients with Previ..
AQ
2021EXELIXIS : Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patien..
AQ
2021EXELIXIS : Truist Securities Adjusts Price Target on Exelixis to $36 From $37, Maintains B..
MT
2021EXELIXIS : Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patien..
BU
2021Exelixis, Inc. Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in..
CI
2021EXELIXIS : Gets FDA's Approval for Cabometyx to Treat Thyroid Cancer -- Stock Up 3% After-..
MT
2021EXELIXIS : Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Prev..
BU
2021Exelixis, Inc. Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients wi..
CI
2021EXELIXIS : Says New Exploratory Data from Late-Stage Trial Show Potential of Kidney Cancer..
MT
2021EXELIXIS : Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Reg..
BU
2021Exelixis, Inc Announces CABOMETYX in Combination with OPDIVO® Provides Efficacy Benefit..
CI
2021EXELIXIS' : Chief Medical Officer Passes Away
MT
2021EXELIXIS : Statement on the Passing of Two Senior Executives
BU
2021Exelixis, Inc. Announces Passing of Gisela M. Schwab, M.D., President, Product Developm..
CI
2021EXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
BU
2021Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX (cabo..
AQ
2021EXELIXIS : Partner Takeda Secures Cabometyx Combo Nod in Japan for Metastatic Renal Cell C..
MT
2021EXELIXIS : Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabo..
BU
2021Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive ..
CI
2021EXELIXIS : Expands Oncology Collaboration With Invenra
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on EXELIXIS, INC.